

Emanuele Carosati

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7495474/publications.pdf>

Version: 2024-02-01

42
papers

2,223
citations

236612

25
h-index

253896

43
g-index

48
all docs

48
docs citations

48
times ranked

3276
citing authors

#	ARTICLE	IF	CITATIONS
1	MetaSite:Â Understanding Metabolism in Human Cytochromes from the Perspective of the Chemist. <i>Journal of Medicinal Chemistry</i> , 2005, 48, 6970-6979.	2.9	466
2	Hydrogen Bonding Interactions of Covalently Bonded Fluorine Atoms:Â From Crystallographic Data to a New Angular Function in the GRID Force Field. <i>Journal of Medicinal Chemistry</i> , 2004, 47, 5114-5125.	2.9	218
3	A Novel Approach for Predicting P-Glycoprotein (ABCB1) Inhibition Using Molecular Interaction Fields. <i>Journal of Medicinal Chemistry</i> , 2011, 54, 1740-1751.	2.9	141
4	1,4-Dihydropyridine Scaffold in Medicinal Chemistry, The Story So Far And Perspectives (Part 2): Action in Other Targets and Antitargets. <i>Current Medicinal Chemistry</i> , 2012, 19, 4306-4323.	1.2	104
5	FLAP: GRID Molecular Interaction Fields in Virtual Screening. Validation using the DUD Data Set. <i>Journal of Chemical Information and Modeling</i> , 2010, 50, 1442-1450.	2.5	94
6	1,4-Dihydropyridine Scaffold in Medicinal Chemistry, The Story so Far And Perspectives (Part 1): Action in Ion Channels and GPCRs. <i>Current Medicinal Chemistry</i> , 2011, 18, 4901-4922.	1.2	86
7	IAP antagonists: promising candidates for cancer therapy. <i>Drug Discovery Today</i> , 2010, 15, 210-219.	3.2	85
8	Pyrazolo[4,3- <i>c</i>][1,2]benzothiazines 5,5-Dioxide: A Promising New Class of <i>Staphylococcus aureus</i> NorA Efflux Pump Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2012, 55, 3568-3572.	2.9	82
9	Discovery of Novel Inhibitors of the NorA Multidrug Transporter of <i>Staphylococcus aureus</i> . <i>Journal of Medicinal Chemistry</i> , 2011, 54, 354-365.	2.9	67
10	Calcium Channel Antagonists Discovered by a Multidisciplinary Approach. <i>Journal of Medicinal Chemistry</i> , 2006, 49, 5206-5216.	2.9	61
11	ADME-Space: a new tool for medicinal chemists to explore ADME properties. <i>Scientific Reports</i> , 2017, 7, 6359.	1.6	58
12	Peptide studies by means of principal properties of amino acids derived from MIF descriptors. <i>Journal of Chemometrics</i> , 2004, 18, 146-155.	0.7	49
13	Virtual Screening for Novel Openers of Pancreatic KATPChannels. <i>Journal of Medicinal Chemistry</i> , 2007, 50, 2117-2126.	2.9	46
14	Comparison of Ligand-Based and Structure-Based 3D-QSAR Approaches:Â A Case Study on (Aryl-)Bridged 2-Aminobenzonitriles Inhibiting HIV-1 Reverse Transcriptase. <i>Journal of Medicinal Chemistry</i> , 2005, 48, 3756-3767.	2.9	45
15	Homodimeric Enzymes as Drug Targets. <i>Current Medicinal Chemistry</i> , 2010, 17, 826-846.	1.2	45
16	Large, chemically diverse dataset of logP measurements for benchmarking studies. <i>European Journal of Pharmaceutical Sciences</i> , 2013, 48, 21-29.	1.9	42
17	From 6-Aminoquinolone Antibacterials to 6-Amino-7-thiopyranopyridinylquinolone Ethyl Esters as Inhibitors of <i>Staphylococcus aureus</i> Multidrug Efflux Pumps. <i>Journal of Medicinal Chemistry</i> , 2010, 53, 4466-4480.	2.9	41
18	The flavonoid scaffold as a template for the design of modulators of the vascular Ca ^v 1.2 channels. <i>British Journal of Pharmacology</i> , 2011, 164, 1684-1697.	2.7	40

#	ARTICLE	IF	CITATIONS
19	A New Class of Selective Myocardial Calcium Channel Modulators. 2. Role of the Acetal Chain in Oxadiazol-3-one Derivatives. <i>Journal of Medicinal Chemistry</i> , 2005, 48, 2445-2456.	2.9	37
20	Transporter-Mediated Efflux Influences CNS Side Effects: ABCB1, from Antitarget to Target. <i>Molecular Informatics</i> , 2010, 29, 16-26.	1.4	35
21	QSAR Modeling and Data Mining Link Torsades de Pointes Risk to the Interplay of Extent of Metabolism, Active Transport, and hERG Liability. <i>Molecular Pharmaceutics</i> , 2012, 9, 2290-2301.	2.3	33
22	L-Type Calcium Channel Blockers: From Diltiazem to 1,2,4-Oxadiazol-5-ones via Thiazinooxadiazol-3-one Derivatives. <i>Journal of Medicinal Chemistry</i> , 2009, 52, 2352-2362.	2.9	29
23	Novel TOPP descriptors in 3D-QSAR analysis of apoptosis inducing 4-aryl-4H-chromenes: Comparison versus other 2D- and 3D-descriptors. <i>Bioorganic and Medicinal Chemistry</i> , 2007, 15, 6450-6462.	1.4	27
24	Discovery of Novel and Cardioselective Diltiazem-like Calcium Channel Blockers via Virtual Screening. <i>Journal of Medicinal Chemistry</i> , 2008, 51, 5552-5565.	2.9	27
25	Diltiazem Analogues: The Last Ten Years on Structure Activity Relationships. <i>Current Medicinal Chemistry</i> , 2007, 14, 279-287.	1.2	26
26	Targeting Cystalyisin, a Virulence Factor of <i>Treponema denticola</i> Supported Periodontitis. <i>ChemMedChem</i> , 2014, 9, 1501-1511.	1.6	26
27	Binding studies and GRIND/ALMOND-based 3D QSAR analysis of benzothiazine type KATP-channel openers. <i>Bioorganic and Medicinal Chemistry</i> , 2005, 13, 5581-5591.	1.4	21
28	Side-Chain Modified Ergosterol and Stigmasterol Derivatives as Liver X Receptor Agonists. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 6548-6562.	2.9	21
29	Ligand-based virtual screening and ADME-tox guided approach to identify triazolo-quinoxalines as folate cycle inhibitors. <i>Bioorganic and Medicinal Chemistry</i> , 2010, 18, 7773-7785.	1.4	20
30	Inhibitor of Ovarian Cancer Cells Growth by Virtual Screening: A New Thiazole Derivative Targeting Human Thymidylate Synthase. <i>Journal of Medicinal Chemistry</i> , 2012, 55, 10272-10276.	2.9	20
31	Ligand Promiscuity between the Efflux Pumps Human P-Glycoprotein and <i>S. aureus</i> NorA. <i>ACS Medicinal Chemistry Letters</i> , 2012, 3, 248-251.	1.3	20
32	Modelling cytochromes P450 binding modes to predict P450 inhibition, metabolic stability and isoform selectivity. <i>Drug Discovery Today: Technologies</i> , 2013, 10, e167-e175.	4.0	15
33	On the catalytic role of the active site residue E121 of <i>E. coli</i> l-aspartate oxidase. <i>Biochimie</i> , 2010, 92, 1335-1342.	1.3	13
34	Stereoselective Behavior of the Functional Diltiazem Analogue 1-[(4-Chlorophenyl)sulfonyl]-2-(2-thienyl)pyrrolidine, a New L-Type Calcium Channel Blocker. <i>Journal of Medicinal Chemistry</i> , 2009, 52, 6637-6648.	2.9	10
35	Understanding Oxadiazolothiazinone Biological Properties: Negative Inotropic Activity versus Cytochrome P450-Mediated Metabolism. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 3340-3352.	2.9	10
36	Absolute configuration and biological profile of two thiazinooxadiazol-3-ones with L-type calcium channel activity: a study of the structural effects. <i>Organic and Biomolecular Chemistry</i> , 2012, 10, 8994.	1.5	9

#	ARTICLE	IF	CITATIONS
37	THREE-DIMENSIONAL QUANTITATIVE STRUCTURE-PROPERTY RELATIONSHIPS. , 2003, , 405-416.		7
38	Playing with Opening and Closing of Heterocycles: Using the Cusmano-Ruccia Reaction to Develop a Novel Class of Oxadiazolothiazinones, Active as Calcium Channel Modulators and P-Glycoprotein Inhibitors. <i>Molecules</i> , 2014, 19, 16543-16572.	1.7	6
39	Combining machine learning and quantum mechanics yields more <sc>chemically aware</sc> molecular descriptors for medicinal chemistry applications. <i>Journal of Computational Chemistry</i> , 2021, 42, 2068-2078.	1.5	6
40	Synthesis and L-type calcium channel blocking activity of new chiral oxadiazolothiazinones. <i>European Journal of Medicinal Chemistry</i> , 2015, 92, 481-489.	2.6	4
41	Discovery of Novel, Potent, and Specific Cellâ€Death Inducers in the Jurkat Acute Lymphoblastic Leukemia Cell Line. <i>ChemMedChem</i> , 2015, 10, 1700-1706.	1.6	0
42	Integrating Crystallography into Early Metabolism Studies. <i>NATO Science for Peace and Security Series A: Chemistry and Biology</i> , 2009, , 63-77.	0.5	0